Maxim analyst Naz Rahman downgraded Alimera Sciences (ALIM) to Hold from Buy after ANI Pharmaceuticals (ANIP) agreed to acquire Alimera for $5.50 per share in cash upfront and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences Set for Merger with ANI Pharmaceuticals
- ANI Pharmaceuticals sees ‘substantial accretion’ from Alimera Sciences deal
- ANI Pharmaceuticals to acquire Alimera Sciences for $381M upfront
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences reports Q1 EPS (12c), consensus (6c)